Pharmacokinetic and Safety of Dexlansoprazole in Adolescents With Gastroesophageal Reflux Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00847210|
Recruitment Status : Completed
First Posted : February 19, 2009
Results First Posted : October 5, 2010
Last Update Posted : February 2, 2012
|Condition or disease||Intervention/treatment||Phase|
|Gastroesophageal Reflux||Drug: Dexlansoprazole MR||Phase 1|
Gastroesophageal reflux disease is a condition of multifactorial etiology resulting in the reflux of gastric contents into the esophagus through the lower esophageal sphincter. The prevalence of Gastroesophageal reflux disease in the pediatric population is becoming increasingly recognized and documented. It is a chronic disease that can persist through adulthood with symptoms in older children and adolescents being similar to those seen in adults. The prevalence of gastroesophageal reflux disease increases with age, from 2.5% of children between the ages of 3 and 9 years, to 8.5% of those between the ages of 10 and 17 years.
Younger children generally present with extra-esophageal manifestations, regurgitation, and epigastric pain, while older children and adolescents typically present with adult-type gastroesophageal reflux disease symptoms of heartburn and regurgitation. Treatment for gastroesophageal reflux disease is aimed at alleviating symptoms and healing the esophageal inflammation.
This study evaluated the pharmacokinetics and safety of dexlansoprazole MR in the pediatric population (ages 12-17) and determined if the pharmacokinetic profile is similar to that in adults given the same dose.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||36 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase 1, Randomized, Open-Label, Parallel Group, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole Modified Release Capsules (30 mg and 60 mg) in Adolescents With Symptomatic Gastroesophageal Reflux Disease|
|Study Start Date :||May 2009|
|Actual Primary Completion Date :||September 2009|
|Actual Study Completion Date :||September 2009|
|Experimental: Dexlansoprazole MR 30 mg QD||
Drug: Dexlansoprazole MR
Dexlansoprazole MR 30 mg, capsules, orally, once daily for up to 7 days.
|Experimental: Dexlansoprazole MR 60 mg QD||
Drug: Dexlansoprazole MR
Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to 7 days.
- Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) Pharmacokinetic Parameter [ Time Frame: After 7 days of dosing. ]Tmax: Time to reach the Maximum Plasma Concentration (Cmax), equal to time (hours) to Cmax, as observed on Day 7.
- Cmax: Maximum Observed Plasma Concentration Pharmacokinetic Parameter. [ Time Frame: After 7 days of dosing. ]Maximum Observed Plasma Concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.
- AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration Pharmacokinetic Parameter. [ Time Frame: After 7 days of dosing. ]Area Under the Plasma Concentration Versus Time Curve (AUC(0-tlqc)) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]).
- AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose Pharmacokinetic Parameter. [ Time Frame: After 7 days of dosing. ]AUC(0-24) is measure of Area Under the Curve over the dosing interval (tau) (AUC(0-tau]), where tau is the length of the dosing interval - 24 hours in this study).
- Terminal Phase Elimination Half-life (T1/2) Pharmacokinetic Parameter. [ Time Frame: After 7 days of dosing. ]Terminal Phase Elimination Half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.
- Oral Clearance (CL/F) Pharmacokinetic Parameter. [ Time Frame: After 7 days of dosing. ]CL/F is apparent clearance of the drug from the plasma, calculated as the drug dose divided AUC(0-24), expressed in L/hr.
- Terminal Elimination Rate Constant (λz) Pharmacokinetic Parameter. [ Time Frame: After 7 days of dosing. ]Terminal elimination rate constant (λz) is the rate at which drugs are eliminated from the body.
- Apparent Volume of Distribution (Vz/F) Pharmacokinetic Parameter. [ Time Frame: After 7 days of dosing. ]Vz/F is the distribution of a drug between plasma and the rest of the body following oral administration, calculated as CL/F divided by λz.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00847210
|United States, California|
|Anaheim, California, United States|
|Cypress, California, United States|
|United States, Kansas|
|Overland Park, Kansas, United States|
|Study Director:||Medical Director Pharmacovigilance||Takeda|